Senior Research Associate/Associate Scientist

Shape Therapeutics

Shape Therapeutics

51-200 employees

Pioneering programmable RNA medicines using AI

Data & Analytics
AI & Machine Learning

$72,000 - $98,000

Annual target bonus, Sign-on bonus, Equity grant, Relocation bonus


Cambridge, MA, USA + 1 more

Required Skills
Data Analysis
  • B.S. degree in a relevant scientific discipline with over 4 years of experience or an M.S. with over 2 years (industry experience preferred)
  • Proficient in cloning techniques (standard, Gibson, Golden Gate) and a wide range of molecular biology protocols (including DNA/RNA purification, various PCR methods, and NGS library prep)
  • Skilled in mammalian cell culture and transfection, with a familiarity with high-throughput screening applications
  • Lab automation knowledge is advantageous
  • Good grasp of gene editing technologies and RNA handling
  • Proactive, solution-focused approach with a strong analytical mindset
  • Independent yet team-oriented, with excellent time management for multitasking
  • Exceptional attention to detail and commitment to clear, proactive communication
  • Execute tissue culture and transfection to evaluate RNAfix™ payload effectiveness
  • Aid in expanding AI-driven gRNA design models through significant data generation
  • Conduct plasmid cloning and apply molecular biology techniques including DNA/RNA isolation, cDNA synthesis, and quantitative PCR methods
  • Perform sequencing (Sanger and NGS) to assess gRNA efficacy
  • Design and carry out well-controlled experiments, maintaining rigorous attention to detail
  • Work in sync with Research Therapeutics and Analytics and Informatics teams on payload evaluation
  • Present results clearly in both written and verbal formats
  • Manage time efficiently to adhere to project timelines
  • Keep a meticulous and current electronic lab notebook and assist in lab management and supply procurement

Shape Therapeutics Inc. (ShapeTX) is a pioneer in the field of programmable RNA medicines, leveraging a robust AI-driven platform to analyze vast datasets and design effective treatments for a wide range of diseases, from rare genetic disorders to debilitating conditions like Alzheimer's and Parkinson's. The company's unique approach utilizes ADAR, a naturally occurring enzyme, to correct protein-making instructions by recoding RNA, offering a potential solution to numerous genetic disorders without permanently altering DNA. Additionally, ShapeTX's TruStable™ stable cell lines significantly enhance the manufacturability of RNA medicines at any scale, ensuring accessibility for patients.

Company Stage

Series B

Total Funding



Seattle, Washington



Growth & Insights

6 month growth


1 year growth


2 year growth